PMID- 17680909
OWN - NLM
STAT- MEDLINE
DCOM- 20071004
LR  - 20220316
IS  - 0905-6157 (Print)
IS  - 0905-6157 (Linking)
VI  - 18
IP  - 6
DP  - 2007 Sep
TI  - Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy 
      in house dust mite-allergic children with asthma.
PG  - 508-15
AB  - Although sublingual immunotherapy (SLIT) is accepted to be a viable alternative 
      of specific-allergen immunotherapy, the efficacy of long-term SLIT in asthmatic 
      children is not well established. The efficacy of 3 yr of SLIT in addition to 
      pharmacotherapy was compared with pharmacotherapy alone in a prospective, open, 
      parallel-group, controlled study. Children with asthma aged 4-16 yr, sensitive to 
      house dust mite (HDM) were followed up for a run-in period of 1 yr and then 
      grouped as those who would receive SLIT + pharmacotherapy (n = 62) or 
      pharmacotherapy alone (n = 28). All patients were evaluated based on 
      symptom-medication scores and lung function tests every 3 months, as well as 
      skin-prick test and serum total immunoglobulin E (IgE) levels annually for 3 yr. 
      Children in the SLIT + pharmacotherapy group demonstrated significantly lower 
      mean daily dose and annual duration of inhaled corticosteroid (ICS) usage when 
      compared with controls. At the end of the 3 yr, within-group comparisons revealed 
      statistically significant decreases in the dose and duration of ICS only in the 
      SLIT group. Furthermore, 52.4% of subjects in the SLIT + pharmacotherapy group 
      were able to discontinue ICS treatment for at least 6 months, which was only 9.1% 
      for the pharmacotherapy group. Three years of SLIT as an adjunct to 
      pharmacotherapy resulted in reduction of both the duration and dose of ICSs and 
      successful discontinuation of ICSs along with improvement in lung functions in 
      HDM-allergic children with asthma.
FAU - Ozdemir, Cevdet
AU  - Ozdemir C
AD  - Division of Pediatric Allergy and Immunology, School of Medicine, Marmara 
      University, Istanbul, Turkey. cozdemir@superonline.com
FAU - Yazi, Didem
AU  - Yazi D
FAU - Gocmen, Izlem
AU  - Gocmen I
FAU - Yesil, Ozlem
AU  - Yesil O
FAU - Aydogan, Metin
AU  - Aydogan M
FAU - Semic-Jusufagic, Aida
AU  - Semic-Jusufagic A
FAU - Bahceciler, Nerin N
AU  - Bahceciler NN
FAU - Barlan, Isil B
AU  - Barlan IB
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Pediatr Allergy Immunol
JT  - Pediatric allergy and immunology : official publication of the European Society 
      of Pediatric Allergy and Immunology
JID - 9106718
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antigens, Dermatophagoides)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 51333-22-3 (Budesonide)
SB  - IM
MH  - Administration, Inhalation
MH  - Administration, Sublingual
MH  - Adolescent
MH  - Adrenal Cortex Hormones/administration & dosage/*therapeutic use
MH  - Animals
MH  - Anti-Asthmatic Agents/administration & dosage/*therapeutic use
MH  - Antigens, Dermatophagoides/*administration & dosage
MH  - Asthma/drug therapy/immunology/*therapy
MH  - Budesonide/administration & dosage/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy
MH  - Desensitization, Immunologic/*methods
MH  - Female
MH  - Humans
MH  - Hypersensitivity/drug therapy/immunology/*therapy
MH  - Immunoglobulin E/blood
MH  - Infant
MH  - Male
MH  - Prospective Studies
MH  - Pyroglyphidae/*immunology
MH  - Respiratory Function Tests
MH  - Skin Tests
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2007/08/08 09:00
MHDA- 2007/10/05 09:00
CRDT- 2007/08/08 09:00
PHST- 2007/08/08 09:00 [pubmed]
PHST- 2007/10/05 09:00 [medline]
PHST- 2007/08/08 09:00 [entrez]
AID - PAI549 [pii]
AID - 10.1111/j.1399-3038.2007.00549.x [doi]
PST - ppublish
SO  - Pediatr Allergy Immunol. 2007 Sep;18(6):508-15. doi: 
      10.1111/j.1399-3038.2007.00549.x.